Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:07 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of LY3526318 in Healthy Male Japanese Participants
NCT05580250 · Eli Lilly and Company · PHASE1 · withdrawn · last registry update 2026-09-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The sponsor made a business decision to withdraw the trial.” | – | Registry record, Eli Lilly and Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HMGCR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-02Phase 3 first posted: First Affiliated Hospital of Wannan Medical College, Atorvastatin + Hybutimibe 10mg QD (NCT07908875)
- 2026-10-19Results posted on the registry: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, DC-806 + Midazolam (NCT06092931)
- 2026-10-09Results posted on the registry: Beth Israel Deaconess Medical Center, Enoxaparin + Enoxaparin + Rosuvastatin (NCT03532139)
- 2026-10-07Also stopped (withdrawn): Dr. Md. Alimur Reza, Atorvastatin 10 mg and ezetimibe 10 mg + Atorvastatin 20 mg (NCT06789432)
- 2026-10-05Also stopped (withdrawn): The George Institute, Atorvastatin (NCT06559072)
- 2026-08-06Also stopped (terminated): Chang Gung Memorial Hospital, Ursodeoxycholic Acid (URSO) + Simvastatin (NCT07102979)
- 2026-07-31Results posted on the registry: University of California, San Diego, Simvastatin (40mg) (NCT02490527)
- 2026-07-30Phase 3 first posted: Assiut University, PCSK9 inhibitor plus rosuvastatin 20 mg tab + Rosuvastatin 20 Mg Oral Tablet (NCT07736313)
- 2026-07-10Results posted on the registry: Eli Lilly and Company, LY3502970 + Placebo (NCT03929744)
- 2026-07-09Results posted on the registry: Sony Tuteja, Rosuvastatin + Placebo (NCT04098003)
- 2026-06-01Phase 3 first posted: AstraZeneca, laroprovstat/rosuvastatin 1 + laroprovstat/rosuvastatin 2 (NCT07619118)
- 2026-06-01Phase 3 first posted: AstraZeneca, Laroprovstat + Rosuvastatin 1 (NCT07619131)
- 2026-05-22Results posted on the registry: Eli Lilly and Company, Orforglipron + Simvastatin (NCT06186622)
- 2026-05-22Also stopped (terminated): Henan Institute of Cardiovascular Epidemiology, Rosuvastatin 20 mg + Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA] (NCT05613426)
- 2026-05-14Results posted on the registry: University of Texas Southwestern Medical Center, Polypill + Usual Care (individual medications prescribed by primary cardiologist) (NCT05514938)
- 2026-05-14Phase 3 first posted: Middle East North Africa Stroke and Interventional Neurotherapies Organization, Alirocumab + Placebo (NCT07586540)
- 2026-05-12Also stopped (withdrawn): Bayer, Nurandociguat + Rosuvastatin (NCT07515339)
- 2026-05-07Results posted on the registry: Columbia University, Statin + Atorvastatin (NCT02850081)
- 2026-05-07Also stopped (terminated): Columbia University, Statin + Atorvastatin (NCT02850081)
- 2026-05-04Phase 3 first posted: Celltrion Pharm, Inc., Amlodipine + Ezetimibe/Rosuvastatin (NCT07564726)
- 2026-04-27Also stopped (terminated): Seoul National University Hospital, Vitamin C and Vitamin E + Statin (NCT03228238)
- 2026-04-23Also stopped (suspended): Sclnow Biotechnology Co., Ltd., Allogeneic umbilical cord mesenchymal stem cell + Aspirin Enteric-coated Tablets & Atorvastatin Calcium (NCT03176498)
- 2026-04-21Results posted on the registry: Basilea Pharmaceutica, pitavastatin + pitavastatin single dose combined with ceftobiprole (NCT06808646)
- 2026-04-15Phase 3 first posted: Children's Hospital of Fudan University, atorvastatin of dose level 1 + atorvastatin of dose level 2 (NCT07530640)
- 2026-04-14Results posted on the registry: Novartis Pharmaceuticals, Inclisiran Sodium + Placebo (NCT05192941)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision